A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

Condition:   Virus Diseases Interventions:   Biological: Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A);   Biological: Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A);   Biological: High dose formulation of RG SAM (CNE) vaccine (GSK3903133A);   Drug: Saline Placebo;   Biological: RabAvert Sponsor:   GlaxoSmithKline Not yet recruiting

Source: ClinicalTrials.gov - August 20, 2019 Category: Research Source Type: clinical trials